Skip to main content

Table 4 Utility and challenges of social media listening

From: Utility of social media and crowd-intelligence data for pharmacovigilance: a scoping review

Utility and challenges of social media listening

Count (%)

Utility of social media listening for pharmacovigilance

 Supplemental data to traditional post-marketing safety surveillance

31 (44.3%)

 Captures perceptions and consequences of treatment and adverse events

14 (20.0%)

 Large publicly available data source

14 (20.0%)

 Able to discover undocumented or rare adverse events

11 (15.7%)

 Promising early warning system

10 (14.3%)

 Computationally efficient

7 (10.0%)

 Captures prescription drug misuse/abuse

4 (5.7%)

 Not biased towards severe adverse events

7 (10.0%)

 Captures large geographical area

3 (4.3%)

 Useful for risk communication

3 (4.3%)

 Able to extract complex medical concepts

2 (2.9%)

 Can be more accurate than spontaneous reporting systems

2 (2.9%)

 Hypothesis-generating

2 (2.9%)

 Able to identify undocumented drug interactions

2 (2.9%)

 Findings are similar to traditional systems

1 (1.4%)

 Captures information on adherence related to adverse events

1 (1.4%)

Challenges of social media listening for pharmacovigilance

 Non-standard reporting format (informal language, format used to report information, amount of information provided by each user)

30 (42.9%)

 Difficult to draw complex semantic relationships from unstructured texts

14 (20.0%)

 May not be a representative population

13 (18.6%)

 Noise may exist in signal detection

12 (17.1%)

 Inadequate information to draw causality

9 (12.9%)

 Lacks comprehensive medical and demographic information

8 (11.4%)

 Subjective, incomplete or misinformation

6 (8.6%)

 Not a balanced coverage of all drugs and medical conditions

5 (7.1%)

 Data acquisition challenges due to host site restrictions

4 (5.7%)

 Duplication of data (double-counting)

4 (5.7%)

 Processing multi-lingual texts

3 (4.3%)

 Resource-intensive to process big data

2 (2.9%)